Outlook in oral and cutaneous Kaposi's sarcoma

We looked at survival of 138 patients with HIV-1-associated Kaposi's sarcoma. Patients with lesions of the oral mucosa had a higher death rate (risk ratio 3·4 [95% CI 1·6–7·1]; p=0·001) than those having exclusively cutaneous manifestations of the disease. Patients with oral Kaposi's sarco...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2000-12, Vol.356 (9248), p.2160-2160
Main Authors: Rohrmus, Bettina, Thoma-Greber, Eva M, Bogner, Johannes R, Röcken, Martin
Format: Article
Language:English
Subjects:
Antiretroviral agents
Germany - epidemiology
Health risks
HIV
HIV Infections - complications
Human immunodeficiency virus
Humans
Lesions
Lymphocytes
Mortality
Mortality risk
Mouth Neoplasms - mortality
Mouth Neoplasms - virology
Regression analysis
Sarcoma
Sarcoma, Kaposi - mortality
Sarcoma, Kaposi - virology
Skin
Skin Neoplasms - mortality
Skin Neoplasms - virology
Survival
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We looked at survival of 138 patients with HIV-1-associated Kaposi's sarcoma. Patients with lesions of the oral mucosa had a higher death rate (risk ratio 3·4 [95% CI 1·6–7·1]; p=0·001) than those having exclusively cutaneous manifestations of the disease. Patients with oral Kaposi's sarcoma and a CD4 cell count of at least 150/μL had a similar mortality risk to patients with the cutaneous disease but CD-4 cell concentration of no more than 150/μL. Thus, oral Kaposi's sarcoma is an important prognostic marker, at least for patients who do not receive triple antiretroviral therapy.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(00)03503-0